Lisata Therapeutics holds annual shareholder meeting
LSTA•Lisata Therapeutics shareholders approved a reverse stock split ranging from 1-for-5 to 1-for-15 at the November 9, 2026, annual meeting. They also approved equity plans, elected two directors and ratified Grant Thornton LLP as auditor; a vote on preferred stock conversion was deferred to November 30.
1. Shareholder votes
Shareholders authorized Lisata Therapeutics to effect a reverse stock split ranging from 1-for-5 to 1-for-15. They approved the equity incentive plan, with an initial reserve of 44,764,472 shares, and the employee stock purchase plan, with an initial reserve of 3,730,372 shares.
2. Other meeting results
Cynthia L. Flowers and Dr. Ted W. Love were elected directors, and stockholders ratified Grant Thornton LLP as independent auditor for the year ending December 31, 2026. Shareholders authorized adjournment, while voting on conversion of Series C Non-Voting Convertible Preferred Stock was deferred to November 30, 2026.
